Immuron Limited (ASX:IMC) Stock Falls: What Investors Need to Know About Its Travelan Sales

Sonal Goyal

06 November 2026 09:31 PM AEDT

Immuron Limited (ASX:IMC) Stock Falls: What Investors Need to Know About Its Travelan Sales

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Immuron (ASX:IMC) shares finished the 6 November 2026 session at $0.035, down 12.50%.
Global Q1 FY27 sales were A$2.2 million, up 9% on the prior comparative period, on unaudited figures.
Australian Travelan sales rose 14% on the prior comparative period after a Brand relaunch.

During the Trading session on 6 November 2026, Immuron Limited (ASX:IMC) shares finished at $0.035, down 12.50%, while the S&P/ASX 200 fell 0.49% to 9,020.80. Immuron is a biopharmaceutical company listed on the ASX and NASDAQ, with its Travelan product sold in several markets. Its latest update is the Q1 FY27 sales announcement dated 27 October 2026.

Latest Development: Q1 FY27 Sales (27 October 2026)

Immuron reported unaudited global sales of A$2.2 million for the quarter ended 30 September 2026, up 9% on the prior comparative period and up 5% on the prior quarter.

Australian sales were A$1.8 million, up 14% on the prior comparative period, which the company attributed to the Travelan brand relaunch with new packaging and brand communications. Canadian sales were A$0.1 million, while US sales were A$0.3 million, down 19% on the prior comparative period.

About the Company

Immuron develops and sells Travelan, an oral immunotherapy product used for travel-related gastrointestinal protection, across Australia, Canada and the United States.

Sector Context

Consumer health and biopharmaceutical products depend on regulatory status, distribution and brand support. Sales can vary with travel patterns and Marketing activity.

Risks to Watch

US sales fell in the quarter, and the company's growth depends on the Australian relaunch being sustained. The figures are unaudited and may change. Commercial sales alone may not cover the company's broader development costs.

What Lies Ahead

Investors will be watching for the audited FY27 results, the trend in US sales and the outcome of further brand and distribution initiatives.

Final Word

The sales update shows growth in global and Australian sales over the prior comparative period, with a decline in the United States. The next period's figures will indicate whether the relaunch effect continues.

FAQs

Q: What were global Q1 sales?

A: A$2.2 million, up 9% on the prior comparative period, on unaudited figures.

Q: Why did Australian sales grow?

A: The company attributed the growth to the Travelan brand relaunch.

Q: What happened in the US?

A: US sales were A$0.3 million, down 19% on the prior comparative period.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.